
India’s tariff agreement with the US removes its earlier disadvantage versus peers (50% falls to 18%, which is at the lower end of the spectrum). While details are awaited, in our view, India is unlikely to have conceded much on agriculture. This deal raises India’s export coverage under trade deals to ~70%. The economy had adjusted to 50% tariffs: overall exports were up (exempt sectors like electronics and pharma grew, commodities like shrimp diversified away from the US; sectors under 232 had no disadvantage), as was tech FDI. But this deal helps affected sectors (gems & jewellery, leather, plastics, ceramics and auto comps.) and non-tech FDI. Sentiment on INR should turn (as already visible).
The US-India agreement on tariffs is only notionally better than Asian peers (18% is 1-2pp below Vietnam, Bangladesh and Indonesia; Korea/TW/JP are at 15% but are not really competitors and have committed investments but clears the road for investments. While details are awaited, India is unlikely to have offered meaningful concessions on agriculture, in our view. With the tariff disadvantage removed, India’s export coverage under trade agreements will rise to 70%, with high complementarity for the US. Together with the duty relaxations announced in the budget and QCO removals, this opens the Indian economy up further, with a positive impact on productivity.
Between Sep-Nov-2025, when US tariffs were 50%, overall export growth was stronger than over FY22-25. However, sectors affected by the tariffs (gems & jewellery, leather, plastics, paper and ceramic/stones had seen exports fall YoY. This should now reverse as lower tariffs are effective immediately. Exports of commodity sectors (agri & allied products like shrimps, metals and chemicals) had diversified away from the US and were growing YoY anyway, though US share fell (‘Resistants’): they may see some gains too. This deal does not affect sectors under Section 232 (e.g. steel) that have the same tariffs for all countries, or those with exemptions (e.g. electronics or pharma.
Even if the US Supreme Court invalidates IEEPA linked tariffs, the effective rate for India, through a mix of statutes, may not be very different from 18%. India’s economy had adjusted to 50% tariffs: (i) total exports grew (transhipment; commodities diverting to other markets); and (ii) tech FDI sustained. But lower official tariffs will help build momentum for non-tech FDI as uncertainty is reduced. More than any meaningful rise in portfolio flows into debt/equity, the negative sentiment on INR should reverse (as early trends confirm).
To read the full report Click Here